Overview

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

This study evaluated the clinical response of the efficacy and safety of the combination therapy of peginterferon alfa-2a and ribavirin, compared with an antiviral treatment-free group in CHC patients with compensated LC. Additionally, this study evaluated the dosage reactivity and the pharmacokinetic characteristics of the combination therapy of peginterferon alfa-2a and ribavirin in CHC patients with compensated LC.

Phase:

Phase 3

Details

Lead Sponsor:

Chugai Pharmaceutical

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin